Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chakrabarti Capital Management is a private investment firm and family office that focuses on the life sciences, pharmaceutical, and specialty chemicals sectors. The firm serves as the strategic investment vehicle for the Chakrabarti family, the founders and owners of the global conglomerate PMC Group. It specializes in the acquisition, turnaround, and management of companies within the pharmaceutical supply chain, with a particular emphasis on active pharmaceutical ingredient (API) manufacturing and CDMO services. Notable historical transactions include the acquisition of the German API manufacturer PharmaZell and the French CDMO PMC Isochem. The firm is known for its long-term investment horizon and its ability to integrate complex chemical manufacturing assets into its global portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chakrabarti Capital Management.